Key takeaways from Saudi Arabia's National Biotechnology Strategy

In January 2024, Saudi Arabia released its National Biotech Strategy, an ambitious plan to localise biomanufacturing, incentivise R&D and establish the Kingdom as the regional biotech leader by 2030, and an internationally recognised hub by 2040. 

What is the national biotechnology strategy of Saudi Arabia, and what does it hope to achieve? Here are five key takeaways:

1.    Realising Vision 2030 goals

The National Biotechnology Strategy is closely aligned with Saudi Arabia's Vision 2030, contributing directly to 11 strategic objectives and indirectly impacting 26 others. The strategy will play a pivotal role in achieving national development targets, including enhancing healthcare access, promoting environmental sustainability, boosting international investment and new economic opportunities.

2.    Economic diversification

By prioritising biotechnology, Saudi Arabia aims to diversify its economy and reduce reliance on oil revenue. The strategy sets ambitious targets to contribute over US$34.6 billion to the non-oil GDP by 2040. This focus on economic growth positions the biotech sector as a cornerstone of Saudi Arabia's future prosperity.

3.    Healthcare innovation

The strategy highlights the transformative potential of biotechnology in improving healthcare outcomes for KSA citizens. Through initiatives such as genomics research, vaccine development, and biosimilar production, the Kingdom seeks to reduce reliance on imported drugs, and increase access to innovation therapies, ultimately extending average life expectancy by five years by 2040. The strategy will also be an important driver in talent development for the region, creating 11,000 high-quality, innovative job opportunities by 2030, and 55,000 by 2040.

4.    Biotech leadership

Saudi Arabia aims to establish itself as a leading hub for biotechnology in the MENA region by 2030 and a global player by 2040. The strategy emphasises collaboration with international partners to drive scientific advancements and foster multinational cooperation in research and development. This collaborative approach positions the KSA as a key player in shaping the future of biotechnology on a global scale.

5.    A localised industry

The National Biotechnology Strategy represents a concerted effort by government bodies to structure and develop the domestic biotech industry. By providing essential enablers such as sustainable talent development, cutting-edge infrastructure, regulatory excellence, strategic funding, and a conducive geographical model, the strategy lays the foundation for the sector's growth and success. International pharma will play a key, collaborative role in helping to realise these ambitions, through tech-transfer, talent, and shared expertise.
The KSA accounts for 60% of the pharma market in the Gulf, making it well-placed as the home of a brand-new event for the region – CPHI Middle East. 

Set to be the region’s most comprehensive pharma gathering, the exhibition will bring together regional drug manufacturers and global suppliers of raw materials, machinery, packaging solutions, contract services, biopharma, and finished dosage. 

Beyond partnering and networking opportunities, CPHI Middle East will offer an extensive content programme, including a dedicated Biologics track, offering attendees the chance to hear from industry thought leaders, to build expertise, and to understand the wealth of future opportunities. 

CPHI is coming to Saudi Arabia – a place at the forefront of innovation in pharma, where you can make endless connections. See more about the region's largest gathering of pharmaceutical experts here.

CPHI Middle East will bring together regional drug manufacturers with global suppliers of raw materials, machinery, packaging solutions, contract services, biopharma, and finished dosage. Download the exhibitor brochure here.